News Updates
More Articles
- CHMP recommends deucravacitinib for plaque psoriasis
- CHMP backs Sandoz's high-concentration adalimumab
- Efanesoctocog alfa shows effectiveness in hemophilia
- Forged labels linked to contaminated cough syrup
- Pfizer backs Ribon Therapeutics with $25M investment
Consortium to develop pan-cancer blood assay
Under the Dutch-Swiss consortium Mainline, Lausanne University Hospital, PamGene International and Alithea Genomics will collaborate on a pan-cancer blood assay to predict the safety and efficacy of immune checkpoint inhibitor treatment. The consortium, which has Eurostars grant funding worth $1.1 million, will develop a transcriptomics biomarker panel and a pan-cancer predictive kinome profile and will use blood samples from eligible patients for validation and training of the model. 360Dx (tiered subscription model) (1/17)
Read full article now.
×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!